INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $44,199 | +207.9% | 2,384 | +83.7% | 0.00% | +100.0% |
Q2 2023 | $14,356 | -17.6% | 1,298 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $17,432 | -15.6% | 1,298 | -22.3% | 0.00% | 0.0% |
Q4 2022 | $20,658 | -11.3% | 1,670 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $23,297 | +1.0% | 1,670 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $23,063 | -15.1% | 1,670 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $27,171 | -75.9% | 1,670 | -75.9% | 0.00% | -50.0% |
Q4 2021 | $112,906 | -3.9% | 6,931 | -12.4% | 0.00% | 0.0% |
Q3 2021 | $117,538 | -25.6% | 7,915 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $158,063 | -13.5% | 7,915 | 0.0% | 0.00% | -33.3% |
Q1 2021 | $182,678 | -6.6% | 7,915 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $195,501 | -40.4% | 7,915 | 0.0% | 0.00% | -50.0% |
Q3 2020 | $328,156 | -13.5% | 7,915 | 0.0% | 0.01% | -14.3% |
Q2 2020 | $379,208 | -19.5% | 7,915 | +5.8% | 0.01% | -30.0% |
Q1 2020 | $471,067 | -52.1% | 7,482 | -5.6% | 0.01% | -37.5% |
Q4 2019 | $982,686 | +82.5% | 7,930 | -2.3% | 0.02% | +77.8% |
Q3 2019 | $538,379 | -8.2% | 8,113 | +10.1% | 0.01% | -10.0% |
Q2 2019 | $586,351 | -26.9% | 7,369 | +2.8% | 0.01% | -33.3% |
Q1 2019 | $802,036 | +11.0% | 7,170 | 0.0% | 0.02% | +7.1% |
Q4 2018 | $722,664 | -20.2% | 7,170 | 0.0% | 0.01% | -12.5% |
Q3 2018 | $906,001 | -99.8% | 7,170 | 0.0% | 0.02% | +60.0% |
Q2 2018 | $601,635,000 | +632.0% | 7,170 | +436.7% | 0.01% | +900.0% |
Q1 2018 | $82,191,000 | +105273.1% | 1,336 | +0.1% | 0.00% | 0.0% |
Q4 2017 | $78,000 | 0.0% | 1,335 | -1.1% | 0.00% | – |
Q3 2017 | $78,000 | -49.7% | 1,350 | +5.4% | 0.00% | -100.0% |
Q2 2017 | $155,000 | +22.0% | 1,281 | +13.8% | 0.00% | 0.0% |
Q1 2017 | $127,000 | +4.1% | 1,126 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $122,000 | -37.1% | 1,126 | -4.4% | 0.00% | 0.0% |
Q3 2016 | $194,000 | +10.2% | 1,178 | -4.5% | 0.00% | 0.0% |
Q2 2016 | $176,000 | +14.3% | 1,234 | +3.2% | 0.00% | 0.0% |
Q1 2016 | $154,000 | -14.0% | 1,196 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $179,000 | -7.3% | 1,196 | +2.7% | 0.00% | 0.0% |
Q3 2015 | $193,000 | -31.3% | 1,164 | 0.0% | 0.00% | -50.0% |
Q2 2015 | $281,000 | +6.0% | 1,164 | +23.7% | 0.00% | 0.0% |
Q1 2015 | $265,000 | +93.4% | 941 | +7.1% | 0.00% | +100.0% |
Q4 2014 | $137,000 | -32.5% | 879 | +2.7% | 0.00% | 0.0% |
Q3 2014 | $203,000 | -0.5% | 856 | -0.7% | 0.00% | 0.0% |
Q2 2014 | $204,000 | -89.0% | 862 | -84.7% | 0.00% | -92.3% |
Q1 2014 | $1,856,000 | +380.8% | 5,628 | -0.4% | 0.01% | +333.3% |
Q4 2013 | $386,000 | -1.0% | 5,652 | 0.0% | 0.00% | 0.0% |
Q3 2013 | $390,000 | +54.2% | 5,652 | 0.0% | 0.00% | +50.0% |
Q2 2013 | $253,000 | – | 5,652 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |